## Diagnosis: AL Amyloidosis ### Clinical Presentation Pattern This patient presents with the classic triad of **cardiac, renal, and hepatic involvement** — the hallmark of systemic AL (light chain) amyloidosis. The restrictive cardiomyopathy with preserved ejection fraction and concentric hypertrophy is pathognomonic for cardiac amyloidosis. ### Key Diagnostic Features | Feature | AL Amyloidosis | AA Amyloidosis | Aβ2M Amyloidosis | |---------|---|---|---| | **Primary source** | Misfolded immunoglobulin light chains (κ or λ) | Serum amyloid A (acute phase reactant) | β2-microglobulin | | **Organ involvement** | Heart, kidneys, liver, nerves (multisystem) | Kidneys, liver, spleen (AA) | Bones, joints, carpal tunnel (dialysis-related) | | **Cardiac pattern** | Restrictive cardiomyopathy, conduction blocks | Rare cardiac involvement | No cardiac involvement | | **Renal involvement** | Nephrotic syndrome (common) | Nephrotic syndrome (common) | Minimal | | **Associated condition** | Plasma cell dyscrasia (may be occult) | Chronic infection (TB, osteomyelitis), chronic inflammation (RA) | Chronic hemodialysis | | **Median survival** | 2–4 years (untreated) | 5–10 years | Variable | **Key Point:** AL amyloidosis is the most common form of systemic amyloidosis in developed countries and the only type with cardiac involvement as a dominant feature. ### Pathophysiology 1. Clonal plasma cell population produces misfolded light chains (κ > λ in AL) 2. Light chains escape renal filtration and deposit in tissues 3. Form β-pleated sheet structure → Congo red binding → apple-green birefringence under polarized light 4. Tissue infiltration → organ dysfunction (heart: restrictive pattern; kidney: proteinuria; liver: hepatomegaly) **Clinical Pearl:** The combination of **restrictive cardiomyopathy + nephrotic syndrome + hepatomegaly** is virtually diagnostic of AL amyloidosis until proven otherwise. ### Diagnostic Confirmation - **Congo red staining** of tissue biopsy (myocardium, kidney, fat pad) with **polarized light microscopy** showing apple-green birefringence ✓ (present in this case) - **Immunofluorescence** or **immunoelectron microscopy** of biopsy to identify light chain type (κ or λ) - **Serum and urine protein electrophoresis** to detect monoclonal spike (may be absent in ~10% of AL) - **Free light chain assay** (elevated κ/λ ratio) - **Bone marrow biopsy** to assess plasma cell burden **High-Yield:** The Congo red positivity with birefringence under polarized light is the **gold standard for amyloid identification** — this finding is pathognomonic and must be confirmed in any suspected amyloidosis. ### Why This Patient Has AL, Not Other Types - **Not AA:** No history of chronic infection (TB, osteomyelitis) or chronic inflammatory disease (RA, IBD). AA amyloidosis rarely causes cardiac involvement. - **Not Aβ2M:** No history of chronic hemodialysis. Aβ2M causes bone/joint disease and carpal tunnel syndrome, not cardiac restriction. - **Not AE (lysozyme):** Extremely rare; causes renal disease but not cardiac involvement. ### Management Implications - Urgent plasma cell assessment (SPEP, UPEP, free light chain assay, bone marrow biopsy) - Cardiac imaging: ECG (low voltage despite LVH — classic), echocardiography, cardiac MRI - Chemotherapy (bortezomib-based regimens) or stem cell transplantation for eligible patients - Supportive care: ACE inhibitors (carefully — risk of hypotension), diuretics, avoid calcium channel blockers (negative inotropes) **Mnemonic — AL Amyloidosis = "All organs involved":** Amyloid Light chain → multisystem disease (Cardiac, Renal, Hepatic, Neurologic)
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.